The Efficacy of Dupilumab as an Adjuvant Treatment After Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps: A Retrospective Cohort Analysis.

IF 3.4 3区医学 Q1 OTORHINOLARYNGOLOGY

Clinical and Experimental Otorhinolaryngology Pub Date : 2025-08-01 Epub Date: 2025-04-08 DOI:10.21053/ceo.2024.00310

Chin-Nung Liu, Te-Huei Yeh, Chih-Feng Lin, Yi-Tsen Lin

{"title":"The Efficacy of Dupilumab as an Adjuvant Treatment After Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps: A Retrospective Cohort Analysis.","authors":"Chin-Nung Liu, Te-Huei Yeh, Chih-Feng Lin, Yi-Tsen Lin","doi":"10.21053/ceo.2024.00310","DOIUrl":null,"url":null,"abstract":"Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) demonstrates a high recurrence rate following endoscopic sinus surgery (ESS). The role of adjunctive biologic therapy remains incompletely understood. This study aims to assess the efficacy of dupilumab when used in conjunction with ESS for patients with CRSwNP.Methods: We conducted a retrospective cohort study of type 2 CRSwNP patients who underwent ESS. The study compared patients receiving postoperative dupilumab with those receiving standard care. Changes in the Lund-Kennedy endoscopic score (LKES) and nasal polyp score (NPS) were recorded, and linear mixed models (LMMs) were employed for the primary outcome analysis.Results: The study enrolled 49 CRSwNP patients, with 22 patients in the dupilumab group. Postoperative LKES and NPS decreased in both groups. LMM analysis revealed a significant improvement in LKES (B=-0.61; 95% CI, -0.90 to -0.31; P<0.001) and a more pronounced improvement in NPS (B=-0.14; 95% CI, -0.25 to -0.02; P=0.025) in the dupilumab group compared to controls from preoperative to postoperative measurements.Conclusion: Compared to ESS alone, the adjunctive use of dupilumab in the postoperative period was associated with greater reductions in both NPS and endoscopic scores.","PeriodicalId":10318,"journal":{"name":"Clinical and Experimental Otorhinolaryngology","volume":" ","pages":"271-279"},"PeriodicalIF":3.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400147/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Otorhinolaryngology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21053/ceo.2024.00310","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) demonstrates a high recurrence rate following endoscopic sinus surgery (ESS). The role of adjunctive biologic therapy remains incompletely understood. This study aims to assess the efficacy of dupilumab when used in conjunction with ESS for patients with CRSwNP.

Methods: We conducted a retrospective cohort study of type 2 CRSwNP patients who underwent ESS. The study compared patients receiving postoperative dupilumab with those receiving standard care. Changes in the Lund-Kennedy endoscopic score (LKES) and nasal polyp score (NPS) were recorded, and linear mixed models (LMMs) were employed for the primary outcome analysis.

Results: The study enrolled 49 CRSwNP patients, with 22 patients in the dupilumab group. Postoperative LKES and NPS decreased in both groups. LMM analysis revealed a significant improvement in LKES (B=-0.61; 95% CI, -0.90 to -0.31; P<0.001) and a more pronounced improvement in NPS (B=-0.14; 95% CI, -0.25 to -0.02; P=0.025) in the dupilumab group compared to controls from preoperative to postoperative measurements.

Conclusion: Compared to ESS alone, the adjunctive use of dupilumab in the postoperative period was associated with greater reductions in both NPS and endoscopic scores.

Abstract Image

查看原文本刊更多论文

dupilumab作为内镜鼻窦手术后辅助治疗慢性鼻窦炎伴鼻息肉的疗效：回顾性队列分析。

目的：慢性鼻窦炎合并鼻息肉（CRSwNP）在内镜鼻窦手术（ESS）后复发率高。辅助生物治疗的作用仍有待充分阐明。本研究旨在评估dupilumab联合ESS治疗CRSwNP患者的疗效。方法：我们对接受ESS治疗的2型CRSwNP患者进行了回顾性队列研究。该研究比较了那些接受术后dupilumab治疗的患者和那些接受标准治疗的患者。记录Lund-Kennedy内镜评分（LKES）和鼻息肉评分（NPS）的变化，并使用线性混合模型（lmm）进行主要结局分析。结果：该研究纳入了49例CRSwNP患者，其中22例患者为dupilumab组。两组术后LKES和NPS均下降。与对照组相比，LMM组术前至术后LKESs显著改善（B = -0.61, 95% CI: -0.90至-0.31,P < 0.001）， nps改善更为显著（B = -0.14, 95% CI: -0.25至-0.02,P = 0.025）。结论：与单独使用ESS相比，术后辅助使用dupilumab与鼻息肉评分和内镜评分的更大降低相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Otorhinolaryngology 医学-耳鼻喉科学

CiteScore

4.90

自引率

6.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical and Experimental Otorhinolaryngology (Clin Exp Otorhinolaryngol, CEO) is an international peer-reviewed journal on recent developments in diagnosis and treatment of otorhinolaryngology-head and neck surgery and dedicated to the advancement of patient care in ear, nose, throat, head, and neck disorders. This journal publishes original articles relating to both clinical and basic researches, reviews, and clinical trials, encompassing the whole topics of otorhinolaryngology-head and neck surgery. CEO was first issued in 2008 and this journal is published in English four times (the last day of February, May, August, and November) per year by the Korean Society of Otorhinolaryngology-Head and Neck Surgery. The Journal aims at publishing evidence-based, scientifically written articles from different disciplines of otorhinolaryngology field. The readership contains clinical/basic research into current practice in otorhinolaryngology, audiology, speech pathology, head and neck oncology, plastic and reconstructive surgery. The readers are otolaryngologists, head and neck surgeons and oncologists, audiologists, and speech pathologists.